Custodio Nilton, Lira David, Herrera-Perez Eder, Montesinos Rosa, Castro-Suarez Sheila, Cuenca-Alfaro José, Valeriano-Lorenzo Lucía
Servicio de Neurología, Instituto Peruano de NeurocienciasLima, Peru.
Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica InternacionalLima, Peru.
Front Aging Neurosci. 2017 Aug 22;9:278. doi: 10.3389/fnagi.2017.00278. eCollection 2017.
: Short tests to early detection of the cognitive impairment are necessary in primary care setting, particularly in populations with low educational level. The aim of this study was to assess the performance of Memory Alteration Test (M@T) to discriminate controls, patients with amnestic Mild Cognitive Impairment (aMCI) and patients with early Alzheimer's Dementia (AD) in a sample of individuals with low level of education. : Cross-sectional study to assess the performance of the M@T (study test), compared to the neuropsychological evaluation (gold standard test) scores in 247 elderly subjects with low education level from Lima-Peru. The cognitive evaluation included three sequential stages: (1) screening (to detect cases with cognitive impairment); (2) nosological diagnosis (to determinate specific disease); and (3) classification (to differentiate disease subtypes). The subjects with negative results for all stages were considered as cognitively normal (controls). The test performance was assessed by means of area under the receiver operating characteristic (ROC) curve. We calculated validity measures (sensitivity, specificity and correctly classified percentage), the internal consistency (Cronbach's alpha coefficient), and concurrent validity (Pearson's ratio coefficient between the M@T and Clinical Dementia Rating (CDR) scores). : The Cronbach's alpha coefficient was 0.79 and Pearson's ratio coefficient was 0.79 ( < 0.01). The AUC of M@T to discriminate between early AD and aMCI was 99.60% (sensitivity = 100.00%, specificity = 97.53% and correctly classified = 98.41%) and to discriminate between aMCI and controls was 99.56% (sensitivity = 99.17%, specificity = 91.11%, and correctly classified = 96.99%). : The M@T is a short test with a good performance to discriminate controls, aMCI and early AD in individuals with low level of education from urban settings.
在初级保健环境中，尤其是在低教育水平人群中，进行认知障碍早期检测的简短测试很有必要。本研究的目的是评估记忆改变测试（M@T）在低教育水平个体样本中区分对照组、遗忘型轻度认知障碍（aMCI）患者和早期阿尔茨海默病（AD）患者的性能。：横断面研究，评估M@T（研究测试）的性能，并与来自秘鲁利马的247名低教育水平老年受试者的神经心理学评估（金标准测试）分数进行比较。认知评估包括三个连续阶段：（1）筛查（检测认知障碍病例）；（2）疾病诊断（确定具体疾病）；（3）分类（区分疾病亚型）。所有阶段结果均为阴性的受试者被视为认知正常（对照组）。通过受试者操作特征（ROC）曲线下面积评估测试性能。我们计算了效度指标（敏感性、特异性和正确分类百分比）、内部一致性（克朗巴哈α系数）和同时效度（M@T与临床痴呆评定量表（CDR）分数之间的皮尔逊比率系数）。：克朗巴哈α系数为0.79，皮尔逊比率系数为0.79（<0.01）。M@T区分早期AD和aMCI的AUC为99.60%（敏感性=100.00%，特异性=97.53%，正确分类=98.41%），区分aMCI和对照组的AUC为99.56%（敏感性=99.17%，特异性=91.11%，正确分类=96.99%）。：M@T是一项简短测试，在区分城市环境中低教育水平个体的对照组、aMCI和早期AD方面具有良好性能。
